Articles From: Chimera Investment Corporation Obtains New York Stock Exchange Listing Extension to Chimerix's Brincidofovir (CMX001) Selected for Two Oral Presentations at the 2014 BMT Tandem Meetings


2013/9/3
Chimera Investment Corporation (NYSE: CIM) announced today that it has received an extension for continued listing and trading of the Company’s stock on the New York Stock Exchange (NYSE). The extension granted by the NYSE, which is subject to review by the NYSE on an ongoing basis, provides the Company until January 31, 2014 to file its 2012 Annual Report on Form 10-K with the Securities and Exchange Commission.
Sign-up for Chimera Investment Corporation Obtains New York Stock Exchange Listing Extension investment picks
2013/12/17
DURHAM, N.C., Dec.
Sign-up for Chimerix Added to NASDAQ Biotechnology Index (NBI) investment picks
2014/4/9
DURHAM, N.C., April 9, 2014 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX) , a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced the appointment of M.
Sign-up for Chimerix Announces Appointment of M. Michelle Berrey, M.D., M.P.H. as Chief Executive Officer investment picks
DURHAM, N.C., Oct.
Sign-up for Chimerix Announces Completion of Secondary Offering of Common Stock investment picks
2014/3/7
DURHAM, N.C., March 7, 2014 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX) , a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today reported financial results for the fourth quarter and full year 2013.
Sign-up for Chimerix Announces Fourth Quarter and Full Year 2013 Financial Results investment picks
DURHAM, N.C., Oct.
Sign-up for Chimerix Announces Pricing of Secondary Offering of Common Stock investment picks
2013/10/8
DURHAM, N.C., Oct.
Sign-up for Chimerix Announces Proposed Public Offering of Common Stock investment picks
2013/8/14
DURHAM, N.C., Aug.
Sign-up for Chimerix Announces Second Quarter 2013 Financial Results investment picks
DURHAM, N.C., Nov.
Sign-up for Chimerix Announces Third Quarter 2013 Financial Results investment picks
2013/8/14
Encouraging results from the first proof-of-concept study for adenovirus infection support continued clinical development of CMX001 as a first-in-class broad-spectrum antiviral for prevention of double-stranded DNA viral infections Data accepted for oral late-breaker presentation at the ICAAC Annual Meeting on September 10 th DURHAM, N.C., Aug.
Sign-up for Chimerix Announces Top Line Data From CMX001 Phase 2 Adenovirus Study and Late-Breaker Presentation at ICAAC investment picks
DURHAM, N.C., Dec.
Sign-up for Chimerix Appoints Linda M. Richardson as Chief Commercial Officer investment picks
2014/4/1
DURHAM, N.C., April 1, 2014 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX) , a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced the appointment of Lisa Ricciardi to the Company's Board of Directors.
Sign-up for Chimerix Appoints Lisa Ricciardi to Board of Directors investment picks
DURHAM, N.C., Aug.
Sign-up for Chimerix Elects Rodman L. Drake to Board of Directors investment picks
2014/3/14
DURHAM, N.C., March 14, 2014 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX) today issued a statement thanking the U.S. Food and Drug Administration (FDA) for its collaboration in developing a protocol for the immediate initiation of a 20-patient pilot trial of open-label brincidofovir for the treatment of adenovirus infections in immunocompromised patients.
Sign-up for Chimerix Issues Statement Thanking the FDA for Collaboration in Developing Protocol to Treat Patients With Life-Threatening Adenovirus Infection investment picks
DURHAM, N.C., Sept.
Sign-up for Chimerix Presents Brincidofovir (CMX001) Adenovirus Phase 2 Results investment picks
2014/2/27
DURHAM, N.C., Feb.
Sign-up for Chimerix to Announce Fourth Quarter Financial Results on March 7, 2014 investment picks
DURHAM, N.C., Aug.
Sign-up for Chimerix to Announce Second Quarter Financial Results on August 14, 2013 investment picks
2014/3/24
DURHAM, N.C., March 24, 2014 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX) , a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced an upcoming presentation on its investigational broad-spectrum antiviral brincidofovir (CMX001) at the 40 th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) being held March 30 – April 2, 2014 in Milan, Italy.
Sign-up for Chimerix to Present a Summary of Brincidofovir's (CMX001) Hematologic Safety at the Annual Meeting of the European Group for Blood and Marrow Transplantation investment picks
DURHAM, N.C., Nov.
Sign-up for Chimerix to Present at 25th Annual Piper Jaffray Healthcare Conference investment picks
2013/12/19
DURHAM, N.C., Dec.
Sign-up for Chimerix to Present at 32nd Annual J.P. Morgan Healthcare Conference investment picks
2013/9/6
DURHAM, N.C., Sept.
Sign-up for Chimerix to Present at Morgan Stanley and Stifel Healthcare Conferences in September investment picks
2014/2/3
DURHAM, N.C., Feb.
Sign-up for Chimerix to Present at the 16th Annual BIO CEO & Investor Conference investment picks
DURHAM, N.C., Sept.
Sign-up for Chimerix to Present at the 20th Annual BioCentury NewsMakers Conference investment picks
2014/2/25
DURHAM, N.C., Feb.
Sign-up for Chimerix to Present at the Cowen 34th Annual Health Care Conference investment picks
2014/3/11
DURHAM, N.C., March 11, 2014 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX) today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) for the immediate initiation of a pilot trial of open-label brincidofovir for the treatment of adenovirus infections in immunocompromised patients.
Sign-up for Chimerix to Provide Brincidofovir to Josh Hardy as First Patient in New Open-Label Study in Patients With Adenovirus Infections investment picks
2013/11/5
DURHAM, N.C., Nov.
Sign-up for Chimerix to Report Third Quarter Financial Results on November 14, 2013 investment picks
2014/2/28
DURHAM, N.C., Feb.
Sign-up for Chimerix's Brincidofovir (CMX001) Safety and Antiviral Data Presented at 2014 BMT Tandem Meetings investment picks
2014/2/21
DURHAM, N.C., Feb.
Sign-up for Chimerix's Brincidofovir (CMX001) Selected for Two Oral Presentations at the 2014 BMT Tandem Meetings investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Chimera Investment Corporation Obtains New York Stock Exchange Listing Extension to Chimerix's Brincidofovir (CMX001) Selected for Two Oral Presentations at the 2014 BMT Tandem Meetings
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity